Display options
Cite
Kheradmand F, Hashemnia SM, Valizadeh N, et al. The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells. J Reprod Infertil. 2016;17(2):82-7
Kheradmand, F., Hashemnia, S. M., Valizadeh, N., & Roshan-Milani, S. (2016). The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells. Journal of reproduction & infertility, 17(2), 82-7.
Kheradmand, Fatemeh, et al. "The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells." Journal of reproduction & infertility vol. 17,2 (2016): 82-7.
Kheradmand F, Hashemnia SM, Valizadeh N, Roshan-Milani S. The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells. J Reprod Infertil. 2016 Apr-Jun;17(2):82-7. PMID: 27141462; PMCID: PMC4842238.
Copy Download .nbib Format: NLM
Share it on

J Reprod Infertil. 2016 Apr-Jun;17(2):82-7.

The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells.

Journal of reproduction & infertility

Fatemeh Kheradmand, Seyyed Mohammad Reza Hashemnia, Nasim Valizadeh, Shiva Roshan-Milani

Affiliations

  1. Department of Biochemistry, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.
  2. Department of Biochemistry, Urmia University of Medical Sciences, Urmia, Iran.
  3. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  4. Department of Physiology, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.

PMID: 27141462 PMCID: PMC4842238

Abstract

BACKGROUND: Growth factors play an essential role in the development of tumor and normal cells like testicular leydig cells. Treatment of cancer with anti-cancer agents like imatinib mesylate may interfere with normal leydig cell activity, growth and fertility through failure in growth factors' production or their signaling pathways. The purpose of the study was to determine cellular viability and the levels of, platelet derived growth factor (PDGF) and stem cell factor (SCF) in normal mouse leydig cells exposed to imatinib, and addressing the effect of imatinib on fertility potential.

METHODS: The mouse TM3 leydig cells were treated with 0 (control), 2.5, 5, 10 and 20 μM imatinib for 2, 4 and 6 days. Each experiment was repeated three times (15 experiments in each day).The cellular viability and growth factors levels were assessed by MTT and ELISA methods, respectively. For statistical analysis, one-way ANOVA with Tukey's post hoc and Kruskal-Wallis test were performed. A p-value less than 0.05 was considered statistically significant.

RESULTS: With increasing drug concentration, cellular viability decreased significantly (p<0.05) and in contrast, PDGF levels increased (p<0.05). Different imatinib concentrations had no significant effect on SCF level. Increasing the duration of treatment from 2 to 6 days had no obvious effect on cellular viability, PDGF and SCF levels.

CONCLUSION: Imatinib may reduce fertility potential especially at higher concentrations in patients treated with this drug by decreasing cellular viability. The effect of imatinib on leydig cells is associated with PDGF stimulation. Of course future studies can be helpful in exploring the long term effects of this drug.

Keywords: Cellular viability; Growth factors; Imatinib mesylate; Leydig cells; Platelet derived growth factor; Stem cell factor

References

  1. Br J Haematol. 2007 May;137(4):374-5 - PubMed
  2. J Histochem Cytochem. 2009 Sep;57(9):861-9 - PubMed
  3. J Cell Biol. 2000 May 29;149(5):1019-26 - PubMed
  4. Clin Cancer Res. 2004 May 15;10(10):3528-34 - PubMed
  5. Int J Androl. 2007 Aug;30(4):366-76; discussion 376 - PubMed
  6. Genes Dev. 2003 Mar 15;17(6):800-10 - PubMed
  7. J Invest Dermatol. 2004 Feb;122(2):400-5 - PubMed
  8. J Natl Cancer Inst. 2004 Jan 7;96(1):46-55 - PubMed
  9. Profiles Drug Subst Excip Relat Methodol. 2014;39:265-97 - PubMed
  10. Zhonghua Xue Ye Xue Za Zhi. 2013 Sep;34(9):762-6 - PubMed
  11. Reprod Toxicol. 2011 May;31(4):454-63 - PubMed
  12. Nat Rev Drug Discov. 2002 Jul;1(7):493-502 - PubMed
  13. J Mol Endocrinol. 2012 May 08;48(3):229-40 - PubMed
  14. Braz J Med Biol Res. 2013 Jan;46(1):39-51 - PubMed
  15. Fertil Steril. 1999 Jan;71(1):85-9 - PubMed
  16. Indian J Pharmacol. 2011 Jul;43(4):389-92 - PubMed
  17. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed
  18. J Natl Cancer Inst. 2003 Mar 19;95(6):458-70 - PubMed
  19. Trends Endocrinol Metab. 2002 Jan-Feb;13(1):11-7 - PubMed
  20. J Clin Pharm Ther. 2011 Dec;36(6):673-9 - PubMed
  21. Dev Biol. 2000 Nov 1;227(1):169-82 - PubMed
  22. Leuk Res. 2012 Mar;36(3):271-4 - PubMed
  23. Endocr Rev. 2010 Dec;31(6):916-39 - PubMed
  24. Int J Cancer. 2009 Jan 1;124(1):215-22 - PubMed
  25. Cancer Res. 2005 Mar 1;65(5):1897-903 - PubMed
  26. J Clin Endocrinol Metab. 2002 May;87(5):2310-9 - PubMed
  27. J Mol Endocrinol. 2011 Mar 23;46(2):125-38 - PubMed
  28. Ups J Med Sci. 2012 May;117(2):92-8 - PubMed
  29. Prog Histochem Cytochem. 2014 Sep;49(1-3):1-19 - PubMed
  30. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1314-8 - PubMed
  31. J Clin Oncol. 2002 Mar 15;20(6):1692-703 - PubMed
  32. Biol Pharm Bull. 2003 Aug;26(8):1125-8 - PubMed
  33. J Oncol Pharm Pract. 2014 Aug;20(4):243-8 - PubMed
  34. Reprod Toxicol. 2008 Aug;25(4):442-6 - PubMed
  35. J Oncol Pharm Pract. 2012 Jun;18(2):303-10 - PubMed
  36. Klin Onkol. 2015;28(2):105-11 - PubMed

Publication Types